You are here

Journal of clinical oncology : official journal of the American Society of Clinical Oncology DOI:10.1200/JCO.2013.52.3381

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation.

Publication TypeJournal Article
Year of Publication2014
AuthorsBejar, R, Stevenson, KE, Caughey, B, Lindsley, RC, Mar, BG, Stojanov, P, Getz, G, Steensma, DP, Ritz, J, Soiffer, R, Antin, JH, Alyea, E, Armand, P, Ho, V, Koreth, J, Neuberg, D, Cutler, CS, Ebert, BL
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Date Published2014/08/04
ISSN0732-183X
Abstract

Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with MDS is not known.

URLhttp://jco.ascopubs.org/cgi/pmidlookup?view=long&pmid=25092778
DOI10.1200/JCO.2013.52.3381
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/25092778?dopt=Abstract